JiShi Pharmaceutical-B (02616) will announce the Phase I dose escalation clinical data of PD-1/VEGF/CTLA-4 triple antibody and the latest research design of ROR1 ADC.

Wisdom Financial APP News, Cornerstone Pharmaceuticals-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17th to 21st, 2025. The preliminary clinical data summary of the Phase I dose escalation of Cornerstone Pharmaceuticals' core clinical pipeline CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) and the design summary of the ongoing Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate [ADC]) have already been published on the ESMO official website.